Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram

Molecular Psychiatry

Volumn 19, Issue 9, 2014, Pages 962-964

  Svenningsson, P ^a   Berg, L ^a   Matthews, D ^b   Ionescu, D F ^b   Richards, E M ^b   Niciu, M J ^b   Malinger, A ^b   Toups, M ^c   Manji, H ^b,e   Trivedi, M H ^c   Zarate, C A ^b   Greengard, P ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PROTEIN; PROTEIN P11; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; LIPOCORTIN 2; PHARMACOLOGICAL BIOMARKER; PROTEIN S 100; S100 CALCIUM BINDING PROTEIN A10;

CD3+ T LYMPHOCYTE; CHRONIC DRUG ADMINISTRATION; DRUG RESPONSE; DSM-IV; FLOW CYTOMETRY; FRONTAL CORTEX; GENETIC TRANSCRIPTION; HIPPOCAMPUS; HUMAN; LETTER; MAJOR DEPRESSION; MONOCYTE; NATURAL KILLER CELL; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NUCLEUS ACCUMBENS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUICIDE; ADULT; DEPRESSIVE DISORDER, MAJOR; FEMALE; MALE; METABOLISM;

ADULT; ANNEXIN A2; ANTIDEPRESSIVE AGENTS; BIOMARKERS, PHARMACOLOGICAL; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; MALE; MONOCYTES; S100 PROTEINS;

EID: 84927177561     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.13     Document Type: Letter

References (7)

1. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M et al. Science 2006; 311: 77-80.
2. Warner-Schmidt JL, Flajolet M, Maller A, Chen EY, Qi H, Svenningsson P, Greengard P. J Neurosci 2009; 29: 1937-1946.
3. Oh YS, Gao P, Lee KW, Ceglia I, Seo JS, Zhang X et al. Cell 2013; 152: 831-843.
4. Svenningsson P, Kim Y, Warner-Schmidt J, Oh YS, Greengard P. Nat Rev Neurosci 2013; 14: 673-680.
5. Anisman H, Du L, Palkovits M, Faludi G, Kovacs GG, Szontagh-Kishazi P et al. J Psychiatry Neurosci 2008; 33: 131-141.
6. Schmidt EF, Warner-Schmidt JL, Otopalik BG, Pickett SB, Greengard P, Heintz N. Cell 2012; 149: 1152-1163.
7. Egeland M, Warner-Schmidt J, Greengard P, Svenningsson P. Biol Psychiatry 2010; 67: 1048-1056.